Editorial
Timely Diagnosis and Disclosure of Alzheimer Disease Gives Patients Opportunities to Make Choices
Abstract
More than 5.4 million Americans are known to be living with Alzheimer disease (AD). It is also the sixth leading cause of death in the United States. Bettelheim projected that “unless effective treatment and prevention can be found, by 2050 the number of Americans with dementias will triple to nearly 16 million.”1 Caring for AD patients is difficult and problematic in a number of ways from an ethical standpoint. As the number of individuals diagnosed as having AD increases, the issue of whether to inform a person with known or suspected AD of his or her diagnosis continues to stimulate debate, as it has for the past 2 decades or more.2 It is this author’s opinion that the timely diagnosis and disclosure of AD gives patients opportunities to make choices. Fortunately, advances are being made to improve the precision of the diagnosis of mild to moderate AD, and the therapeutic options now span a wider range of medical, psychiatric, social, and rehabilitative entities.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.